The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: a multi-centre, open-label, clinical study

Adrian Covic¹ and Gabriel Mircescu²

¹Dialysis and Transplantation Center, Parhon University Hospital, Lași, Romania and ²Carol Davila University of Medicine and Pharmacy, Bucharest, Romania

Correspondence and offprint requests to: Adrian Covic; E-mail: acovic@xnet.ro

Abstract

Background. Patients with chronic kidney disease (CKD) often present with iron depletion and iron deficiency anaemia (IDA) because of frequent blood (and iron) loss. Therapy consists of repletion of iron stores and intravenous (i.v.) iron has become the standard care in this setting. However, older i.v. iron preparations have their limitations. This study primarily investigated the safety, and also the efficacy, of ferric carboxymaltose (FCM), a next-generation i.v. iron formulation, given as a bolus-push injection in patients with CKD undergoing maintenance haemodialysis (HD).

Methods. Patients (aged 18–65 years) with IDA undergoing HD received 100–200 mg of iron as FCM via an i.v. bolus-push injection into the HD venous line, two to three times weekly for ≤6 weeks. Safety assessments included incidence of adverse events (AEs). Treatment responders were patients attaining ≥1.0 g/dl increase in haemoglobin (Hb) from baseline at any time during the study. Enrolled patients (safety population) receiving ≥1 dose of study medication were included in the efficacy analyses [intent-to-treat (ITT) population].

Results. Of 163 patients enrolled, 150 (92%) completed the study. The mean ± SD total cumulative dose of iron as FCM administered was 2133.3 ± 57.7 mg. In total, 193 AEs were reported in 89 out of 163 (54.6%) patients. Almost three-quarters of patients (73.6%) received erythropoiesis-stimulating agents (ESAs), but the dose remained stable during the study. Enrolled patients (safety population) receiving ≥1 dose of study medication were included in the efficacy analyses [intent-to-treat (ITT) population].

Out of 162 (61.7%; ITT population) patients were treatment responders, and mean Hb levels increased from 9.1 ± 1.30 g/dl at baseline to 10.3 ± 1.63 g/dl at follow-up.

Conclusions. FCM is well-tolerated and effective in the correction of Hb levels and iron stores in patients with IDA undergoing HD. As changes in anaemia treatment other than i.v. FCM (e.g. increased ESA doses) were not permitted during the study, the clinically relevant increase in Hb in the majority of patients can be solely attributed to efficient iron utilization. The incidence of AEs was as expected for this population.

Keywords: clinical trial; efficacy; ferric carboxymaltose; haemodialysis; iron deficiency anaemia; safety

Introduction

Annual blood losses of around 2.5 l place patients with chronic kidney disease (CKD) undergoing haemodialysis (HD) at particularly high risk of iron store depletion with subsequent iron deficiency anaemia (IDA) [1,2]. Iron deficiency can be defined as absolute or functional [1,3]. Absolute iron deficiency develops as the body’s iron stores become depleted to such a low level that not enough iron is available for the production of haemoglobin (Hb) [4,5]. This is usually indicated by a decline in serum ferritin levels to ~<15 μg/l in patients with normal kidney function, but is much higher in patients undergoing HD as a result of chronic inflammation, and is associated with elevated levels of C-reactive protein (CRP) [4,5]. This functional iron deficiency describes the state when iron cannot be mobi-
Ferric carboxymaltose in anaemic patients undergoing haemodialysis

Patients (aged 18 to 65 years) with IDA (Hb <200 μg/l or TSAT <20%), undergoing maintenance HD two to three times per week, were recruited from 24 study centres across three countries (11 centres in South Africa, eight in Romania and five in Lithuania). Patients’ iron status (serum ferritin, TSAT, serum iron and serum transferrin) was assessed up to 7 days before study commencement to justify inclusion. Patients had to be clinically stable without a hospital admission due to renal decompensation during the 4 weeks prior to study inclusion, and a permanent vascular access appropriate for HD was required. Concomitant administration of ESAs was permitted during the study, provided that the patients had started treatment at least 1 month prior to study inclusion and remained on stable doses throughout the trial.

Women of childbearing age had to use reliable forms of contraception throughout the study and for up to 1 month after the final dose of study medication. All patients provided written, informed consent before participating in the study.

Exclusion criteria were: a Hb level <6.5 g/dl, serum ferritin level >500 μg/l, TSAT >50% or serum albumin <2.5 g/dl; known hypersensitivity to iron polysaccharide complexes or to FCM; vitamin B12 or folic acid deficiency; any other type of anaemia; evidence of iron overload conditions (e.g. haemochromatosis); significant cardiovascular disease (including myocardial infarction during the 6 months prior to study inclusion, congestive heart failure New York Heart Association III or IV and poorly controlled hypertension); uncontrolled endocrinological or metabolic disorders; active infection, malignancy, active liver disease, active peptic ulcer, asthma or rheumatoid arthritis; pregnancy or lactation; a history of alcohol or drug abuse; a positive hepatitis B surface antigen or antibody anti-hepatitis C virus test; the need for blood transfusion within 2 months of the start of the study, surgery (with the exception of surgery related to vascular access), treatment with oral or i.v. iron preparations or any investigational drug within 4 weeks prior to study enrolment.

Study design and treatment

The primary objective of this trial was to assess the safety of i.v. iron supplementation as FCM in anaemic patients undergoing HD. The secondary objective was to evaluate the efficacy of FCM in correcting iron deficiency and Hb levels in this patient population. This study was conducted in compliance with the guidelines for Good Clinical Practice and other regulatory requirements.

Eligible patients received 100–200 mg of iron as FCM administered as an i.v. bolus–push injection into the HD venous line 1 h after the start of each dialysis session (two to three sessions per week) for a maximum of 6 weeks. This dose has been found to be well-tolerated when administered as an i.v. infusion of iron sucrose to patients with renal anaemia [16]. The total cumulative dose of iron given to a patient depended on the patient’s individual iron deficit (Ganzoni formula: Iron deficit [mg] = b.w. [kg] × (target Hb – actual Hb) [g/dl] × 2.4 + depot iron [mg] where b.w. is body weight, Hb is haemoglobin, target Hb = 15 g/dl, factor 2.4 = 0.0034 (iron content Hb ≅ 0.34%) × 0.07 [blood volume ≅ 7% of b.w.] × 1000 [conversion grammes to milligrammes] × 10 [conversion litre to decilitre], and depot iron is 500 mg for patients >35 kg body weight. In patients with a body mass index (weight [kg]/(height [m] × height [m])) >25, a normalized weight was used to calculate the iron deficit. For patients <66 kg, the calculated cumulative dose is rounded down to the nearest 100 mg. For patients >66 kg, the calculated cumulative dose is rounded up to the nearest 100 mg. Normalized weight [kg] = 25 × height [m] × height [m]). [17]. A maximum of 600 mg iron was administered weekly; the cumulative maximum dose of FCM did not exceed 2400 mg of iron. Study medication was halted if serum ferritin levels exceeded 500 μg/l or TSAT was >50%. Following the final administration of study medication, patients entered an observation period for up to 1 month. Patient assessments took place every 2 weeks from baseline, with a final follow-up assessment at the end of the observation period. For some patients who withdrew or discontinued early, the follow-up visit took place as soon as possible afterwards, irrespective of the week of final medication.

Materials and methods

Patients

Patients (aged 18 to 65 years) with IDA (Hb ≤11.0 g/dl and either serum ferritin ≤200 μg/l or TSAT <20%), undergoing maintenance HD two to three times per week, were recruited from 24 study centres across three countries (11 centres in South Africa, eight in Romania and five in Lithuania). Patients’ iron status (serum ferritin, TSAT, serum iron and serum transferrin) was assessed up to 7 days before study commencement to justify inclusion. Patients had to be clinically stable without a hospital admission due to renal decompensation during the 4 weeks prior to study inclusion, and a permanent vascular access appropriate for HD was required. Concomitant administration of ESAs was permitted during the study, provided that the patients had started treatment at least 1 month prior to study inclusion and remained on stable doses throughout the trial.

Women of childbearing age had to use reliable forms of contraception throughout the study and for up to 1 month after the final dose of study medication. All patients provided written, informed consent before participating in the study.

Exclusion criteria were: a Hb level <6.5 g/dl, serum ferritin level >500 μg/l, TSAT >50% or serum albumin <2.5 g/dl; known hypersensitivity to iron polysaccharide complexes or to FCM; vitamin B12 or folic acid deficiency; any other type of anaemia; evidence of iron overload conditions (e.g. haemochromatosis); significant cardiovascular disease (including myocardial infarction during the 6 months prior to study inclusion, congestive heart failure New York Heart Association III or IV and poorly controlled hypertension); uncontrolled endocrinological or metabolic disorders; active infection, malignancy, active liver disease, active peptic ulcer, asthma or rheumatoid arthritis; pregnancy or lactation; a history of alcohol or drug abuse; a positive hepatitis B surface antigen or antibody anti-hepatitis C virus test; the need for blood transfusion within 2 months of the start of the study, surgery (with the exception of surgery related to vascular access), treatment with oral or i.v. iron preparations or any investigational drug within 4 weeks prior to study enrolment.

Study design and treatment

The primary objective of this trial was to assess the safety of i.v. iron supplementation as FCM in anaemic patients undergoing HD. The secondary objective was to evaluate the efficacy of FCM in correcting iron deficiency and Hb levels in this patient population. This study was conducted in compliance with the guidelines for Good Clinical Practice and other regulatory requirements.

Eligible patients received 100–200 mg of iron as FCM administered as an i.v. bolus-push injection into the HD venous line 1 h after the start of each dialysis session (two to three sessions per week) for a maximum of 6 weeks. This dose has been found to be well-tolerated when administered as an i.v. infusion of iron sucrose to patients with renal anaemia [16]. The total cumulative dose of iron given to a patient depended on the patient’s individual iron deficit (Ganzoni formula: Iron deficit [mg] = b.w. [kg] × (target Hb – actual Hb) [gL] × 2.4 + depot iron [mg] where b.w. is body weight, Hb is haemoglobin, target Hb = 15 g/dl, factor 2.4 = 0.0034 (iron content Hb ≅ 0.34%) × 0.07 [blood volume ≅ 7% of b.w.] × 1000 [conversion grammes to milligrammes] × 10 [conversion litre to decilitre], and depot iron is 500 mg for patients >35 kg body weight. In patients with a body mass index (weight [kg]/(height [m] × height [m])) >25, a normalized weight was used to calculate the iron deficit. For patients <66 kg, the calculated cumulative dose is rounded down to the nearest 100 mg. For patients >66 kg, the calculated cumulative dose is rounded up to the nearest 100 mg. Normalized weight [kg] = 25 × height [m] × height [m]). [17]. A maximum of 600 mg iron was administered weekly; the cumulative maximum dose of FCM did not exceed 2400 mg of iron. Study medication was halted if serum ferritin levels exceeded 500 μg/l or TSAT was >50%. Following the final administration of study medication, patients entered an observation period for up to 1 month. Patient assessments took place every 2 weeks from baseline, with a final follow-up assessment at the end of the observation period. For some patients who withdrew or discontinued early, the follow-up visit took place as soon as possible afterwards, irrespective of the week of final medication.

Assessments

Safety and tolerability were assessed by the incidence, severity and relation to study medication of AEs, recorded by the investigator from the first dose of FCM. Also monitored were routine clinical laboratory safety parameters, including clinical laboratory safety parameters, [including 12-lead electrocardiogram (ECG) measurements], CRP and pre- and post-dialysis serum urea values.

Efficacy was assessed by correction of patients’ iron stores and Hb levels; no primary efficacy endpoint was defined. Treatment responders were defined as patients who exhibited an increase of ≥1.0 g/dl in Hb from baseline at any point during the study. All laboratory parameters were determined at local laboratories in each country, and all iron para-
Statistical analyses
This was a single-arm, safety study with no specific hypotheses defined, so no formal sample size calculation was made. However, the probability of at least one patient experiencing a specific AE with an incidence rate of 5% is >99% with 120 patients and the probability with an incidence rate of only 1% is 70.1%. A planned sample size of 150 patients was, therefore, deemed to be adequate to evaluate the safety of FCM in this study.

Safety and efficacy were analysed using descriptive statistics, and for specific variables, 95% confidence intervals (95% CIs) were also used. These 95% CIs were calculated according to the method of Wilson as recommended by Altman et al. [18] for binary data, and as mean ± SE × t for continuous data where SE is the standard error of the mean and t is the upper 97.5 percentile of the appropriate t-distribution. Analyses were performed on observed values only. Analyses of safety data were performed using the safety population (all enrolled patients); efficacy results are described using the intent-to-treat (ITT) population (all enrolled patients who received at least one dose of study medication).

Results

Study patients
Patient recruitment began in July 2003; the final follow-up assessment visit took place in May 2004. A total of 344 patients were screened, of whom 163 (47.4%) comprised the safety population and 162 were included in the ITT population. In total, 150 out of 163 (92.0%) patients completed the study (Figure 1).

The majority of patients were Caucasian, with more men (56.4%) than women enrolled to the study (safety population; Table 1). The most common primary renal disease was glomerulopathy [77 out of 163 (47.2%) patients]. Over three-quarters of the patients were undergoing three HD sessions per week [134 out of 163 (82.2%)], the mean duration of HD was 3.2 years [range, 1–23 years]. Nearly three-quarters of the patients [120 out of 163 (73.6%)] were receiving a stable dose of concomitant ESAs at baseline and for the duration of the study. Individual calculated iron deficits ranged from 933 to 2169 mg.

Treatment
At all HD sessions, 100 or 200 mg of iron as FCM was administered, to a mean total cumulative dose of 2133.3 ± 57.7 mg at HD Session 11. The mean dose of FCM administered was 200 mg iron for the first four HD sessions, with a mean for subsequent infusions ranging between 196.2 mg (HD Session 5) and 160.0 mg (HD Sessions 9 and 10). Five patients cumulatively received more iron [9, 41, 100 (two patients) and 600 mg, respectively] than their calculated requirements. None of these patients developed any adverse clinical symptoms and only one patient with a serum ferritin level of 620 μg/l was subsequently withdrawn from the study.

The mean overall duration of the therapeutic period was 15.9 ± 4.5 days (minimum duration, 3 days; maximum duration, 31 days). The highest cumulative total iron dose administered was 2200 mg in one patient who underwent 11 HD sessions at ∼3-day intervals.

All patients who were receiving ESAs at baseline (ranging from 2000 IU once weekly to 10 000 IU twice weekly) maintained a stable dose throughout the study.

Table 1. Patient demographics and baseline characteristics (safety population; n = 163)

| Safety population | Safety population |
|-------------------|-------------------|
| Age, years | 44.9 ± 12.7 |
| Sex | | |
| Female | 71 (43.6%) |
| Male | 92 (56.4%) |
| Race | | |
| Caucasian | 113 (69.3%) |
| Asian | 5 (3.1%) |
| Black | 20 (12.3%) |
| Mixed race | 25 (15.3%) |
| Height, cm | 168.3 ± 9.1 |
| Weight, kg | 70.8 ± 15.8 |
| Primary renal disease | | |
| Glomerulopathy | 77 (47.2%) |
| Vascular nephropathy | 9 (5.5%) |
| Interstitial nephropathy | 19 (11.7%) |
| Other | 58 (35.6%) |
| Number of weekly HD sessions | | |
| 2 | 29 (17.8%) |
| 3 | 134 (82.2%) |
| Patients receiving ESAs | 120 (73.6%) |
| Duration of HD, years | 3.2 ± 3.0 |
| Hb, g/dl | 9.1 ± 1.3 |
| Serum ferritin, μg/l | 67.3 ± 106.7 |
| TSAT, % | 17.4 ± 9.1 |

Values are expressed as mean ± standard deviation or number (percent) ESAs, erythropoiesis-stimulating agents; Hb, haemoglobin; TSAT, transferrin saturation.

ITT population, Hb, n = 159; serum ferritin and TSAT, n = 145.
Ferric carboxymaltose in anaemic patients undergoing haemodialysis

Table 2. Overview of AEs (safety population; n = 163)

| Body system/preferred term                                      | Number (% of patients experiencing event |
|----------------------------------------------------------------|------------------------------------------|
| At least one AE                                                 | 89 (54.6)                                |
| AEs by worst severity                                           |                                          |
| Mild                                                            | 54 (33.1)                                |
| Moderate                                                        | 26 (16.0)                                |
| Severe                                                          | 8 (4.9)                                  |
| Unknown                                                         | 1 (0.6)                                  |
| At least one serious AE                                         | 12 (7.4)                                 |
| AEs by relation to study drug                                    |                                          |
| Unrelated or unlikely to be related                            | 73 (44.8)                                |
| Possibly or probably related                                    | 16 (9.8)                                 |
| Certainly related                                               | 0                                        |
| Discontinuation of study medication                              | 1 (0.6)                                  |
| Unexpected worsening of pre-existing disease                    | 4 (2.4)                                  |
| AE                                                              | 2 (1.2)                                  |
| Death                                                           |                                          |

AE, adverse event.

Two cases of overdose not reported as AEs and not included in the analysis.

Safety

Adverse events. Intravenous iron as FCM was well-tolerated by patients in this study. In total, 193 AEs were reported in 89 out of 163 patients (54.6%; safety population; Table 2). This incidence of AEs is as expected for a population of chronically ill, multi-morbid patients. The most commonly reported AEs are detailed in Table 3. At least one serious AE was reported in 12 out of 163 (7.4%) patients (Table 4). This number includes two patients who died (one from lung tuberculosis and one from acute heart failure); none of the serious AEs were considered by the investigators to be related to the study medication. Three patients underwent renal transplantation during the study. AEs that were considered by the investigators to be possibly related to the study medication were reported in 13 out of 163 (8.0%) patients, these were nausea, abdominal pain, constipation, eructation, white blood cell count increase, headache, night sweats, pigmentation disorder, hypertension and hypotension; other AEs related to laboratory parameters and included two reports of increased alanine aminotransferase levels and one each of aspartate aminotransferase increase, liver function test abnormality and CRP increase. Only three out of 163 (1.8%) patients reported AEs (nausea, abnormal liver function test and headache) that were considered by the investigators as probably related to study medication.

Five patients (3.1%) were withdrawn from the study prematurely because of an AE (Table 2), these AEs were bronchopneumonia (n = 1), respiratory tract infection with hypertensive episode (n = 1), increased transaminases (n = 1) and renal transplant (n = 2).

There were five cases of accidental overdose, two of which, in patients who received 100 mg iron as FCM, were considered as certainly related to study treatment, but were not reported as AEs and were not part of the AE statistical analysis. The other three cases were reported as AEs and included in the statistical analysis. None of the five patients developed clinical symptoms.

Clinical evaluations. No clinically relevant changes from baseline or during HD sessions in vital signs (blood pressure, heart rate and axillary temperature), physical examinations or ECGs were observed.

Red blood cell and haematocrit values demonstrated an improvement during the study; there were no clinically relevant changes from baseline in reticulocytes. In addition, no clinically relevant changes from baseline in liver function-related clinical chemistry parameters were observed.

Mean CRP values were above the normal range (0–5 mg/l) at all visits, except at screening and the 4-week postbaseline visit. Mildly increased CRP values have frequently been described in patients undergoing HD in the absence of infection or inflammation. CRP increases were recorded in four patients. In one patient, the high CRP value was not due to any underlying clinical condition. The CRP value at the local laboratory was 4 mg/l at baseline, 20 mg/l at

Table 3. Incidence of AEs reported in ≥5 patients (safety population; n = 163)

| Body system/preferred term                                      | Number (% of patients experiencing event |
|----------------------------------------------------------------|------------------------------------------|
| At least one AE                                                 | 89 (54.6)                                |
| Infections and infestations                                     | 24 (14.7)                                |
| Respiratory tract viral infection                               | 6 (3.7)                                  |
| Vascular disorders                                              | 21 (12.9)                                |
| Hypertension                                                    | 13 (8.0)                                 |
| Hypotension                                                     | 8 (4.9)                                  |
| Gastrointestinal disorders                                      | 18 (11.0)                                |
| Nausea                                                          | 5 (3.1)                                  |
| Investigations (laboratory and ECG abnormalities)               | 15 (9.2)                                 |
| Nervous system disorders                                        | 15 (9.2)                                 |
| Headache                                                        | 13 (8.0)                                 |
| Musculoskeletal and connective tissue disorders                 | 13 (8.0)                                 |
| Muscle cramp                                                    | 8 (4.9)                                  |
| Respiratory, thoracic and mediastinal disorders                 | 8 (4.9)                                  |
| Injury, poisoning and procedural complications                  | 5 (3.1)                                  |
| General disorders and administration-site conditions            | 7 (4.3)                                  |
| Skin and subcutaneous tissue disorders                          | 5 (3.1)                                  |
| Surgical and medical procedures                                 | 5 (3.1)                                  |

AE, adverse event; ECG, electrocardiogram.

Table 4. Summary of serious AEs (safety population; n = 163)

| Body system/preferred term                                      | Number (% of patients experiencing event |
|----------------------------------------------------------------|------------------------------------------|
| At least one serious AE                                        | 12 (7.4)                                 |
| Infections and infestations                                    | 4 (2.5)                                  |
| Gastrointestinal disorders                                     | 3 (1.8)                                  |
| Surgical and medical procedures                                | 3 (1.8)                                  |
| Renal transplantation                                          | 3 (1.8)                                  |
| Vascular disorders                                             | 2 (1.2)                                  |
| Cardiac disorders                                              | 1 (0.6)                                  |
| General disorders and administration-site conditions           | 1 (0.6)                                  |
| Psychiatric disorders                                          | 1 (0.6)                                  |
| Respiratory, thoracic and mediastinal disorders                | 1 (0.6)                                  |

AE, adverse event.
2 weeks following last administration, 16 mg/l at 4 weeks following last administration and 7 mg/l at the post-treatment follow-up assessment. The event was considered by the investigator to be possibly related to study medication and mild in intensity. For the other three patients, the events were considered by the investigator to be unrelated to the study medication.

Iron status safety thresholds. Iron status safety thresholds of TSAT >50% or serum ferritin >500 μg/l were exceeded by 28 out of 125 (22.4%) and 55 out of 125 (44.0%) patients, respectively, 2 weeks after the first administration of study medication (safety population, only patients with non-missing measurements), decreasing to seven out of 141 (5.0%) and 22 out of 141 (15.6%) patients, respectively, by the post-treatment follow-up assessment. Of these, treatment with i.v. iron as FCM was halted in only 10 out of 163 (6.1%) patients as their serum ferritin levels exceeded 500 μg/l. One patient, who was given an accidental overdose (600 mg iron as FCM), reached a serum ferritin level of 620 μg/l during the treatment period (and TSAT of 54%) and was withdrawn from the study, although no clinical symptoms were reported. The investigator attributed the excess increases to an overestimation of iron deficit at baseline. Two patients with serum ferritin levels of 634.0 and 678.2 μg/l, respectively, did not halt treatment with study medication as the stopping rules were not followed. Transitory elevations in iron parameters (ferritin levels >800 μg/l) occurred in five out of 163 (3.1%) patients at some point during the study. However, only one patient was withdrawn due to a ferritin level of 1649 μg/l; this was not associated with any clinical symptoms.

Efficacy

The number of responders, measured by an increase from baseline in Hb of ≥1.0 g/dl, increased at each visit and was achieved by 100 out of 162 (61.7%) patients by the time of the follow-up visit (ITT population; Figure 2). Mean Hb levels increased from 9.1 ± 1.30 g/dl (95% CI = 8.86; 9.26) at baseline to 9.5 ± 1.34 g/dl (95% CI = 9.25; 9.72) at 2 weeks after the first administration of study medication and continued to increase through the observation period to reach 10.3 ± 1.63 g/dl (95% CI = 10.06; 10.58) at follow-up (ITT population; Figure 3). The mean change in Hb 2 weeks following the first administration of study medication was 0.53 ± 0.75 g/dl (95% CI = 0.40; 0.67).

Both serum ferritin levels and TSAT were suboptimal at baseline (67.3 ± 106.73 μg/l and 17.4 ± 9.10%, respectively), as defined by international recommendations [1,19]. However, within the 2 weeks following the first administration of FCM, serum ferritin levels and TSAT had increased to within their respective target ranges (200–500 μg/l serum ferritin and >20% TSAT) [19] for patients undergoing HD (512.7 ± 241.36 μg/l and 38.4 ± 17.23%, respectively) and, although decreasing slightly, remained in the target range until the final follow-up visit (333.6 ± 209.05 μg/l and 31.0 ± 11.00%, respectively; ITT population; Figure 4). Although no formal statistical analysis was planned, the results were considered to be clinically relevant. These
data suggest that FCM was successful in increasing iron stores.

**Discussion**

Patients undergoing HD are unable to maintain their iron balance because of chronic blood (and, therefore, iron) loss at each dialysis session. The initial levels of Hb would indicate that, despite the widespread use of ESAs, although in relatively low doses, reduced iron levels and baseline inflammatory status contributed to the incomplete response to ESA therapy. The initial levels were below the target set for patients with CKD [1]. However, according to the Kidney Disease Outcomes Quality Initiative (KDOQI) 2007 guidelines [19], in patients undergoing HD receiving ESA therapy with a Hb target in the range of 11.0–12.0 g/dl, the proportion of patients who achieve this target in a single month may be 30% or less [19]. Using the National Health and Nutritional Examination Survey, it was found that low levels of iron (serum ferritin <100 μg/l or TSAT <20%) were present in the majority of patients with CKD not undergoing dialysis with reduced creatinine clearance [20] and was associated with absent bone marrow iron in ~80% of patients [21].

HD induces an inflammatory state that accounts for the associated increased serum hepcidin levels [22]. Hepcidin blocks iron absorption from the duodenum and iron release from the liver (the main iron store) and macrophages, thereby interrupting iron recycling [4,23]. The decreased availability of iron for erythropoiesis aggravates the existing anaemia of chronic disease (functional iron deficiency) in HD patients. Oral iron therapy does not lead to normalization of iron stores, as it is not well-absorbed, is poorly tolerated and is associated with low compliance [1,24]. Therefore, in order to maintain an optimal iron status, it is strongly recommended that patients with CKD who are undergoing HD receive supplemental iron intravenously rather than orally [1,19]. This study demonstrates that 200 mg i.v. iron as FCM, administered by bolus-push injection into the HD venous line, is both well-tolerated and effective in increasing Hb levels and iron stores for patients undergoing HD who require treatment for IDA. The majority of patients (61.7%) were treatment responders, achieving a clinically relevant increase in Hb levels of ≥1.0 g/dl at any time during the study after receiving iron as FCM. The observed clinically relevant increases in Hb levels from 9.1 g/dl at baseline to 10.3 g/dl by the follow-up visit in the majority of patients can be solely attributed to the administration of i.v. iron as FCM, as changes in anaemia treatment such as increases in the dosage of ESAs were not permitted during the trial.

There is concern, however, among medical personnel regarding the safety of earlier formulations of parenteral iron. These concerns primarily relate to the potential for excess iron to produce reactive oxygen species that can increase oxidative tissue damage in patients with chronic inflammatory disease: vasoactive reactions that may occur when larger doses of i.v. iron are administered quickly and the incidence of anaphylactic reactions (occasionally fatal) that occur as a consequence of pre-formed anti-dextran antibodies to i.v. iron dextran [1].

In this study, over 90% of participating patients completed iron supplementation with FCM. As expected for a
population of chronically ill, multi-morbid patients, more than half of the patients (54.6%) reported an AE. However, <10% of the patients [16 out of 163 (9.8%)] reported an AE considered by the investigators to be possibly or probably related to study medication, and neither of the two deaths that occurred during the study was considered to be related to study medication. The most frequently reported AEs were respiratory tract viral infection, hypertension, hypotension,
Ferric carboxymaltose in anaemic patients undergoing haemodialysis 2729

muscle cramps, nausea and headache. There were no clinically relevant changes in vital signs or physical examinations.

Another recently developed i.v. iron formulation, ferumoxytol, may be also applied by rapid i.v. injections (two doses of 510 mg iron may be given 3–8 days apart), but in contrast to FCM, it contains dextran derivatives [25]. Significantly increased Hb levels in comparison to oral iron were reported in Phase III trials involving patients with CKD requiring HD [26] as well as patients not on dialysis [27].

The main limitation of this study was its open-label, single-arm design. However, as the primary aim was to evaluate safety, and efficacy was assessed by laboratory parameters, no comparator was necessary. Nevertheless, it may be difficult to conclude the extent to which the reported AEs are related to the study treatment rather than the effects of HD.

In a Phase I dose-escalation study, up to 1000 mg iron as FCM, given as an i.v. infusion over 15 min for doses of over 100 mg iron, was well-tolerated in patients with mild IDA [15]. Recently presented clinical data also support the favourable safety and efficacy profile of i.v. iron as FCM [28,29]. Studies have demonstrated that, compared with oral (FeSO4) or i.v. iron as iron sucrose, significant improvements in Hb levels can be achieved with i.v. iron as FCM in both anaemic patients with non-dialysis-dependent CKD [28] and in HD patients with IDA [29]. Furthermore, treatment with iron as FCM resulted in a lower incidence of drug-related AEs during treatment compared with the earlier supplemental iron preparations [30].

According to Geisser et al. [13], the toxic effects of an iron complex can be forecast by the physiochemical properties (molecular mass, kinetic and thermodynamic stability) of the compound. FCM is a strong and robust iron complex and, as such, demonstrates the properties of an ideal iron compound. Owing to the high structural homogeneity and slow degradation kinetics of FCM, i.v. administration results in a low toxicity and targeted delivery of iron to the reticuloendothelial system and its distribution to the bone marrow, liver and spleen [4,14]. In a second step, the complex is metabolized and the iron is slowly and competitively delivered to endogenous iron-binding proteins. The reticuloendothelial uptake is thought to illustrate, indirectly, the safety of i.v. iron polysaccharide complexes with regard to the long-term effects on the parenchyma of different organs.

Conclusion

In conclusion, i.v. iron as FCM administered by bolus-push injection was well-tolerated in this safety study with a population of anaemic patients undergoing HD. The incidence of AEs reported during the study was as expected for a chronically ill patient population, and no new safety concerns were raised. None of the serious AEs and none of the AEs that led to discontinuation of the study medication were considered related to FCM. Furthermore, FCM was effective in correcting anaemia and refilling the iron stores of this population, which translated into a clinically meaningful increase in Hb, TSAT and serum ferritin levels. This study supports FCM as a new treatment for IDA, offering patients an effective supplemental iron formulation with a good safety profile.

Acknowledgements. The authors take full responsibility for the content of the paper but thank Laura Giles DPhil (Caudex Medical; supported by Vifor International Inc.) for her assistance in preparing the initial draft of the manuscript and collating the comments of the authors and other named contributors. The study was sponsored by Vifor International Inc.

Conflict of interest statement. Adrian Covic has participated in a speaker bureau for Amgen and Roche and has acted as a scientific consultant for FMC. Gabriel Mirecescu had no involvement that might raise the question of bias in the work reported or in the conclusions, implications or opinions stated. The results presented in this paper have not been published previously in whole or part.

References

1. Locatelli F, Aljama P, Barany P et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19: ii1–47
2. Hörl WH. Iron therapy in patients with chronic kidney disease: taking the high road? Port J Nephrol Hypert 2009; 23: 5–10
3. Royal College of Physicians (London). National Collaborating Centre for Chronic Conditions. Anaemia management in chronic kidney disease: national clinical guideline for management in adults and children 2006. Available from: http://www.nice.org.uk/
4. Funk F, Ryle P, Canclini C, Neiser S, Geisser P. The new generation of intravenous iron: chemistry, pharmacology and toxicology of ferric carboxymaltose. Arzneimittelforschung 2010; Supplement: In press
5. World Health Organization. Iron Deficiency Anemia: Assessment, Prevention and Control. Report of a Joint WHO/UNICEF/UNU Consultation 1998
6. US National Kidney Foundation 2008. Available from: http://www.kidney.org/professionals/KDOQI/
7. Hudson JQ, Comstock TJ. Considerations for optimal iron use for anemia due to chronic kidney disease. Clin Ther 2001; 23: 1637–1671
8. Fishbane S. Safety in iron management. Am J Kidney Dis 2003; 41: 18–26
9. Bregman D. Important Drug Warning for Desferrioxamine® (iron dextran injection, USP). Shirley New York: American Regent Inc, 2009;
10. INFeD Prescribing Information. Corona: Watson Pharmaceuticals, Inc., 2009;
11. CosmoFer Summary of Product Characteristics. Holbaek: Pharmacosmos A/S, 2009;
12. Bailie GR, Clark JA, Lane CE, Lane PL. Hypersensitivity reactions and deaths associated with intravenous iron preparations. Nephrol Dial Transplant 2005; 20: 1443–1449
13. Geisser P, Baer M, Schaub E. Structure/histotoxicity relationship of parenteral iron preparations. Arzneimittelforschung 1992; 42: 1439–1452
14. Beshara S, Sorensen J, Lubberink M et al. Pharmacokinetics and red cell utilization of 52Fe/59Fe-labelled iron polymaltose in anaemic patients using positron emission tomography. Br J Haematol 2003; 120: 853–859
15. Geisser P, Banké-Bochita J. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron deficiency anaemia. Arzneimittelforschung 2010; Supplement: In press
16. Chandler G, Harchowal J, Maudougall IC. Intravenous iron sucrose: establishing a safe dose. Am J Kidney Dis 2001; 38: 988–991
17. Ganzoni AM. Intravenous iron-dextran: therapeutic and experimental possibilities. Schweiz Med Wochenschr 1970; 100: 301–303
18. Altman DG, Machin D, Bryant TN, Gardner MS. Statistics with Confidence. 2nd edition. BMJ Books, 2000
19. KDOQI. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anaemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007; 50: 471–530
Electrolysed-reduced water dialysate improves T-cell damage in end-stage renal disease patients with chronic haemodialysis

Kuo-Chin Huang1,*, Shih-Ping Hsu2,3,*, Chih-Ching Yang4,5,*, Pu Ou-Yang2, Kun-Tai Lee6, Shinkatsu Morisawa7, Kazumichi Otsubo7 and Chiang-Ting Chien2

1Department of Family Medicine, National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei, Taiwan, 2Department of Medical Research, National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei, Taiwan, 3Department of Internal Medicine, Far Eastern Memorial Hospital, Taipei, Taiwan, 4Department of Health, Internal Medicine, Far Eastern Memorial Hospital, Taipei, Taiwan, 5Department of Internal Medicine, National Yang-Ming University, Taipei, Taiwan, 6Wan-Hua Regional Hospital, Taipei, Taiwan and 7Nihon-Trim Co., Ltd, Osaka, Japan

*These authors contributed equally to this work.

Correspondence and offprint requests to: Chiang-Ting Chien; E-mail: etchien@ntuh.gov.tw

Abstract

Background. T-cell damage by increased oxidative stress in end-stage renal disease (ESRD) patients undergoing chronic haemodialysis (HD) led to the increased T-cell apoptosis and the alteration of surface markers and Th1/Th2 ratio in CD4+ T lymphocytes. Antioxidant electrolysed-reduced water (ERW) was used as the dialysate in ESRD patients undergoing chronic HD to test for improved oxidative stress-related T-cell apoptosis, alterations of surface markers and intracellular cytokine profile.

Methods. We evaluated apoptosis formation by annexin V, CD25-related surface markers, and cytokine ratio of Th1/Th2 in CD4+ T lymphocytes and Th1/Th2 in CD8+ T lymphocytes of 42 ESRD patients haemodialysed with ERW for 1 year.

Results. In comparison to 12 healthy individuals, the ESRD patients had more T-cell apoptosis and less CD3+ CD4+ and CD8+ T cells and CD25/CD69/CD94/CD21+ phenotypes at baseline. Lower intracellular IL-2 and IFN-γ levels in the Th1/CD4+ and Th1/CD8+ cells and higher intracellular IL-4, IL-6 and IL-10 levels in the Th2/CD4+ and Th2/CD8+ cells were also noted in the ESRD patients. After a 1-year ERW treatment, the patients had a decrease in T-cell apoptosis and increases in CD3+, CD4+ and CD8+ cell numbers and CD25/CD69/CD94/CD21+ phenotypes in the T cells. The intracellular IL-2 and IFN-γ levels in the Th1/Th1 cells significantly (P < 0.05) increased and the intracellular IL-4, IL-6 and IL-10 levels in the Th2/Th2 cells decreased. Furthermore, the Th1/Th2 and Th1/Th2 cytokine ratios were improved toward a normal status.

Conclusion. One-year ERW treatment effectively ameliorated T-cell apoptosis, altered CD25-related surface markers and intracellular cytokine profile in the HD patients.